At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
AZD5069 50mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 4 Week, Double Blind, Placebo Controlled, Randomised, Parallel Group, Multicentre, Phase IIa Study to Investigate the Safety and Tolerability of AZD5069 as Oral Capsules in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
In Brief
A Phase 2 clinical trial evaluating Placebo, AZD5069 50mg, and 1 other intervention for Scientific Terminology Chronic Obstructive Pulmonary Disease (COPD) and Laymen Terminology Chronic Bronchitis and Emphysema. Completed, enrolled 109 participants across 8 sites in 4 countries.
Detailed Summary
The purpose of this study is the evaluate the safety and tolerability of AZD5069 in patients with Chronic Obstructive Pulmonary Disease
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScientific Terminology Chronic Obstructive Pulmonary Disease (COPD), Laymen Terminology Chronic Bronchitis and Emphysema
CountriesBulgaria, Germany, Hungary, Ukraine
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedNov 2010
Primary CompletionMar 2011
TodayJul 2026
First PostedNov 3, 2010
Enrollment StartNov 1, 2010
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 15.7 years ago
Interventions
Placebodrug
Oral dose bid
AZD5069 50mgdrug
Oral dose bid
AZD5069 80mgdrug
Oral dose bid